Latest Breaking News On - Alex fudukidis - Page 4 : comparemela.com

Affimed to Present at the 2022 Jefferies Healthcare Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesBaden wübergAlex fudukidisAdi hoessAlexander fudukidisChief executive officerHealthcare conferenceDaylight timeInvestor relationsGlobe newswire

Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call Transcript

Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

Alex fudukidisAdi hoessAndreas harstrickArndt schotteliusAngus smithWolfgang fischerKarolinska instituteMd anderson cancer centerSecond quarterCorporate update conferenceInvestor relationsChief executive officerChief medical officerChief scientific officerChief operating officerChief financial

Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021

Share: Heidelberg, Germany, April 8, 2021 – Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2020 results and corporate update on Thursday, April 15, 2021. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 4271307 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the Investors section of the company s website at

New yorkUnited statesBaden wubergAlex fudukidisபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesBaden wübergAlex fudukidisNkmax americaDenise chuaAndreas harstrickStephen chenExchange commissionDrug administrationNkmax america incSanta anaAmerica incChief medicalNatural killerChief operating officer